4 results match your criteria: "UCLA Medical Center RHU[Affiliation]"

Objectives: Patients with rheumatoid arthritis (RA) have an excess risk of cardiovascular disease (CVD). We aimed to assess the impact of CVD risk factors, including potential sex differences, and RA-specific variables on CVD outcome in a large, international cohort of patients with RA.

Methods: In 13 rheumatology centres, data on CVD risk factors and RA characteristics were collected at baseline.

View Article and Find Full Text PDF

Objectives: Cardiovascular disease (CVD) risk calculators developed for the general population do not accurately predict CVD events in patients with RA. We sought to externally validate risk calculators recommended for use in patients with RA including the EULAR 1.5 multiplier, the Expanded Cardiovascular Risk Prediction Score for RA (ERS-RA) and QRISK2.

View Article and Find Full Text PDF

A phase 2 study of lower-dose, indomethacin submicron particle capsules demonstrates early onset of acute pain relief.

Clin J Pain

October 2014

*MIG Clinical Research Consulting, San Diego †Division of Rheumatology & Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD ‡Premier Research Group International, LLC, Austin, TX §UCLA Medical Center RHU, Los Angeles, CA ∥Iroko Pharmaceuticals LLC, Philadelphia, PA.

Objectives: Nonsteroidal anti-inflammatory drugs are efficacious for the treatment of acute and chronic pain; however, they have the potential for serious adverse events (AEs). The objective of this study was to evaluate the efficacy and safety of investigational, lower-dose, indomethacin submicron particle capsules compared with placebo in a study of patients with postsurgical pain.

Materials And Methods: This phase 2, multicenter, randomized, double-blind, single-dose, and placebo-controlled study enrolled 203 patients (18 to 50 y old) following extraction of ≥ 2 third molars who experienced moderate-to-severe pain intensity ≤ 6 hours after surgery.

View Article and Find Full Text PDF

Although frequently prescribed to relieve acute pain in patients, non-steroidal anti-inflammatory drugs (NSAIDs) are associated with dose-related gastrointestinal, cardiovascular, and renal complications. Investigational, submicron particle NSAIDs are being developed that could provide effective pain relief at lower doses than currently available oral NSAIDs. This is the first phase 3 study evaluating the analgesic efficacy and safety of lower-dose indomethacin submicron particle capsules in patients following elective surgery.

View Article and Find Full Text PDF